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Abstract
Induction of tolerance against grafted organs is achieved by the immunosuppressive agent cyclosporine, a prominent
member of the calcineurin inhibitors. Unfortunately, its lifetime use is associated with hypertension and nephrotoxicity.
Several mechanism for cyclosporine induced hypertension have been proposed, i.e. activation of the sympathetic nervous
system, endothelin-mediated systemic vasoconstriction, impaired vasodilatation secondary to reduction in prostaglandin
and nitric oxide, altered cytosolic calcium translocation, and activation of the renin-angiotensin system (RAS). In this regard
the molecular basis for undue RAS activation and an increased signaling of the vasoactive oligopeptide angiotensin II (AngII)
remain elusive. Notably, angiotensinogen (AGT) is the precursor of AngII and transcriptional regulation of AGT is controlled
by the hepatic nuclear factor HNF4alpha. To better understand the molecular events associated with cyclosporine induced
hypertension, we investigated the effect of cyclosporine on HNF4alpha expression and activity and searched for novel
HNF4alpha target genes among members of the RAS cascade. Using bioinformatic algorithm and EMSA bandshift assays we
identified angiotensin II receptor type 1 (AGTR1), angiotensin I converting enzyme (ACE), and angiotensin I converting
enzyme 2 (ACE2) as genes targeted by HNF4alpha. Notably, cyclosporine represses HNF4alpha gene and protein expression
and its DNA-binding activity at consensus sequences to AGT, AGTR1, ACE, and ACE2. Consequently, the gene expression of
AGT, AGTR1, and ACE2 was significantly reduced as evidenced by quantitative real-time RT-PCR. While RAS is composed of a
sophisticated interplay between multiple factors we propose a decrease of ACE2 to enforce AngII signaling via AGTR1 to
ultimately result in vasoconstriction and hypertension. Taken collectively we demonstrate cyclosporine to repress
HNF4alpha activity through calcineurin inhibitor mediated inhibition of nuclear factor of activation of T-cells (NFAT) which in
turn represses HNF4alpha that leads to a disturbed balance of RAS.
Citation: Niehof M, Borlak J (2011) HNF4alpha Dysfunction as a Molecular Rational for Cyclosporine Induced Hypertension. PLoS ONE 6(1): e16319. doi:10.1371/
journal.pone.0016319
Editor: Marcelo Bonini, University of Illinois at Chicago, United States of America
Received September 24, 2010; Accepted December 15, 2010; Published January 27, 2011
Copyright:  2011 Niehof, Borlak. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant of the Lower Saxony Ministry of Culture and Science and the Volkswagen Foundation, Germany, to J.B. (grant
number: 25A.5-7251-99-3/00). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: borlak@item.fraunhofer.de
Introduction
Cyclosporine is a potent immunosuppressive agent and widely
used in transplantation medicine and in the treatment of several
autoimmune diseases. However, it is known for a long time that its
clinical application is confounded by unwanted secondary effects,
notably new-onset diabetes, renal dysfunction, renal vascular
damage and arterial hypertension [1–4]. A systematic review of
cyclosporine’s effects on blood pressure was recently reported [5].
There is definitive proof for cyclosporine to increase blood
pressure in a dose-related fashion and was associated with an
increased risk of stroke, myocardial infarction and heart failure.
Likewise, cyclosporine-induced hypertension was observed in
various animal models in vivo, e.g. in mouse [6], rats [7–12],
dogs [13,14], sheep [15], and primates [8,16]. Several mechanism,
including activation of the sympathetic nervous system, endothe-
lin-mediated systemic vasoconstriction, impaired vasodilatation
secondary to reduction in prostaglandin and nitric oxide, altered
cytosolic calcium translocation, and activation of the renin-
angiotensin system (RAS) have been proposed to underlie
cyclosporine-induced hypertension [17–19]. Notably, the RAS
system is a coordinated hormonal cascade playing a key role in the
regulation of blood pressure with the peptide angiotensin II
(AngII) as principle effector. Cyclosporine was reported to elevate
RAS components in transplant patients, e.g. plasma renin activity
[20–22], AngII levels [20–22], angiotensin converting enzyme
(ACE) activity [23,24], or angiotensin receptors (AGTR1) [25–28],
even though the effects of cyclosporine on RAS in man are to
some extend contradictory, since normal or even lower plasma
renin activity had been reported as well [18,29–31]. However, the
lack of increase in plasma renin activity in some clinical studies
does not exclude activation of tissue RAS, which plays additional
important functions but is not necessarily seen as a change in
plasma renin activity [31–33]. Furthermore, cyclosporine also
exerts structural nephrotoxicity which may further increase plasma
renin activity [18,25,34]. Thus, Ras activation may be both a
cause and a consequence of cyclosporine-induced renal damage
[18]. Nevertheless, cyclosporine induced blood pressure changes
occur prior to renal damage [18]. Diverse antihypertensive drugs
are available to treat high blood pressure and clinical trials
evidenced the benefit of inhibitors of RAS, i.e. ACE inhibitors and
AGTR blockers for the prevention of cardiovascular diseases in
the general population [35] as well as in transplant recipients [36].
While several mechanisms including RAS activation had been
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a detailed molecular rational has not been proposed as yet.
Recently, we proposed cyclosporine to repress HNF4a/HNF1a
and subsequent regulation of genes coding for glucose metabolism
and of pancreatic beta-cell function as a molecular rational for
posttransplantation diabetes mellitus, which is an other acknowl-
edged complication in calcineurin inhibitor immunosuppressive
therapies [37]. HNF4a is a master regulatory protein in liver
biology and an important transcription factor in angiotensinogen
(AGT) gene regulation [38]. Specifically, AGT is synthesized in
the liver and secreted into the circulation [39]. It is the substrate of
renin, the rate-limiting enzyme of the RAS enzymatic cascade that
generates the decapeptide angiotensin I (AngI), which then
becomes further processed to the functional vasoactive octapeptide
AngII by activity of the angiotensin I converting enzyme (ACE). It
is known that variation in AGT transcription influences control of
blood pressure [38]. Here, we studied the effect of cyclosporine on
HNF4a and various RAS components to better understand
cyclosporine induced hypertension and proposed HNF4a dys-
function and subsequent regulation of AGTR1, ACE, and ACE2
as a molecular rational.
Materials and Methods
Cell culture experiments
The human hepatoma cell line HepG2 was obtained from LGC-
ATCC Standards (Wesel, Germany). In a dose-range finding study
concentrations of up to 30 mg/mlweretestedforcellviabilitywiththe
MTS assay (CellTiter 96H Aqueous One Solution Cell Proliferation
Assay, Promega, Mannheim, Germany). Thus, HepG2 cells were
treated daily with 10 mg/ml cyclosporine (Sandimmun, Novartis,
Nu ¨rnberg, Germany) for 72 h that represents 8 to 10 times of the
Cmaxseeninpatients[40].Treatmentstarted at 40-50%confluence.
Additionally, HepG2 cells were treated with a combination of
cyclosporine and captopril at 10 mg/ml for 72 h, or alternatively for
4 h with captopril alone after treatment with cyclosporne for 72 h.
Additionally, experiments were carried out with primary human
hepatocytes. Notably, liver specimens were obtained from patients
undergoing hepatic resections at the Medical School of Hannover,
Germany. Written approval for the use of human liver specimens was
obtained from patients undergoing hepatic resections with approval
of the ethics committee of the Medical School of Hannover. Details
regarding the isolation and culture of human hepatocytes in the
collagen sandwich were previously described [41].
Isolation of nuclear extracts, western blotting analysis
and electrophoretic mobility shift assays
The experimental procedures for nuclear extracts isolation,
western blotting analysis and electrophoretic mobility shift assays
(EMSAs) are given in Niehof and Borlak, 2009 [42]. The
antibodies directed against HNF4a (sc-6556x), Actin (sc-1616),
Angiotensinogen (sc-7419), and AGTR1 (sc-1173) were purchased
from Santa Cruz Biotechnology (Heidelberg, Germany). Nuclear
extracts were prepared in triplicate and used as described in the
figure legend. The antigen-antibody complexes were visualized
using the enhanced chemiluminescence (ECL) detection system
(PerkinElmer Life Sciences, Rodgau-Juegesheim, Germany). Light
signal detection was done with the CCD camera Imager system
Kodak IS 440 CF (Kodak, Biostep GmbH, Jahnsdorf, Germany)
and quantification was performed using the Kodak 1D Image
analysis software (version 3.5.). The oligonucleotides (for sequence
information see Table 1) were purchased from MWG Biotech
(Ebersberg/Muenchen, Germany), annealed and
32P-labeled.
Supershift experiments were done with HNF4a specific antibody
(sc-6556x).
Quantitative real-time RT-PCR
Quantitative real-time RT-PCR measurement was done with
the Lightcycler (Roche Diagnostics, Mannheim, Germany) with
the following conditions: denaturation at 95uC, annealing at
different temperatures for 8 sec, elongation at 72uC for different
times and detection of SYBR-Green I-fluorescence at different
temperatures. Detailed primer specific conditions and oligonucle-
otide sequence information are given in Table 2. Relative
quantification was performed using the "Fit Points Method" of
the LightCycler3 Data Analysis Software version 3.5.28 (Roche
Diagnostics, Mannheim, Germany) by comparing the sample
values to a standard curve within the linear range of amplification.
The standardized sample values for each gene of interest were
divided by the standardized values of the housekeeping gene
(mitATPase), which was found to be stably expressed.
Statistical analysis
Experiments are performed at least in triplicate. All values are
expressed as mean 6 standard deviation. To determine signifi-
cance between two groups, comparison was made using the non-
parametric two-tailed Mann-Whitney-U-Test. Therefore, Statis-
tica software, version 8 (StatSoft) was used. The results are
considered significant when the p value was less than 0.05.
Results
Gene expression of members of the renin-angiotensin
system after cyclosporine treatment
Angiotensinogen, a member of the renin-angiotensin system
(RAS), is mainly synthesized in the liver [38]. We therefore used
the HepG2 human hepatoma cell line as model system. Initially,
we studied expression of HNF4a and of members of the RAS
Table 1. Shift-probe sequences.
Gene Oligo name Accession number Sequence
HNF1a HNF1 NM_000545 AGGGCTGAAGTCCAAAGTTCAGTCCCTTC
AGT AGT NM_000029 TGCAGAGGGCAGAGGGCAGGGGA
AGTR1 AGTR1 NM_000685 TAAGGAGGGCAAAGTTCAAGTGA
ACE ACE1 NM_000789 TGGGCCTACCAAAGGTCAGGAGA
ACE2 ACE2(a) NM_021804 AGTCTATGTACTTTGCTCTAGCA
ACE2 ACE2(b) NM_021804 CCGGAGTGATCTTTGACTCTTTC
doi:10.1371/journal.pone.0016319.t001
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time RT-PCR we found HNF4a, angiotensinogen (AGT),
angiotensin receptor 1 (AGTR1), and angiotensin converting
enzyme 2 (ACE2) to be significantly repressed after treatment with
10 mg/ml cyclosporine for 72 h (Fig. 1A). Expression of renin and
angiotensin converting enzyme (ACE) was not detected in HepG2
cells.
Furthermore, at least five splice variants have been identified for
the AGTR1 protein, but only exon 5 encodes the open reading
frame [43,44]. Therefore, we analyzed AGTR1 transcript splice
variants and evidenced expression of AGTR1 for exon 2 [AGTR1
(2/5), Fig. 1A] and exon 5 [AGTR1 (5/5), Fig. 1A] in untreated
HepG2 cells; while expression of exon 3 and exon 4 was not
detected. After treatment of HepG2 cells with cyclosporine
expression of AGTR1 was significantly repressed, but isoform
expression did not change (Fig. 1A). The gene expression of AGT
and AGTR1 was significantly correlated when either untreated or
treated HepG2 cells are studied (Fig. 1B, C).
The consequences of drug treatment with the ACE inhibitor
captoprilwas investigated. For this purpose,HepG2 cellsweretreated
for 72 h with a combination of cyclosporine and captopril (10 mg/ml)
or alternativly for 4 h with captopril alone after treatment with
cyclosporine for 72 h. Repressed gene expression of HNF4a,A G T ,
and AGTR1 by cyclosporine remained unchanged after captopril
treatment under both conditions (Table 3).
To confirm results obtained with HepG2 cell cultures of
primary human hepatocytes were treated with cyclosporine as
well. As observed with the HepG2 cell line HNF4a gene
expression was significantly repressed in cultures of primary
human hepatocytes after treatment with cyclosporine (Fig. 1D).
Cyclosporine inhibits binding of HNF4a to members of
the renin-angiotensin system
It is known that HNF4a binds to promoter elements of AGT
and strongly activates its transcription [38]. We therefore
investigated HNF4a DNA binding activity after cyclosporin
treatment. Importantly, EMSA provided evidence for a cyclo-
sporine dependent decrease in HNF4a DNA-binding to AGT as
well as to the A-site of the HNF1a promoter (HNF1), i.e. an
additional established recognition site for HNF4a (Fig. 2A, B). We
then searched for HNF4a binding sites in proximal promoter
regions of further members of the renin-angiotensin system.
Essentially, the transcription start site (TSS, +1) of the NCBI
mRNA reference sequence (RefSeq) was aligned using the UCSC
Genome Browser (http://genome.ucsc.edu/) for promoter anno-
tation of the respective genes. Proximal promoters (up to –
10000 bp) of human ACE and ACE2, and intronic regions of
human AGTR1 were checked for putative HNF4a binding-sites
with the tool MATCH [45], by employing the Transfac weight
matrix V$HNF4_Q6_01 (generated by Biobase, www.biobase.de).
We detected binding sites within the AGTR1, ACE and ACE2
gene. Binding site positions and scores for matrix similarity and
core similarity are indicated in Table 4. The ability of HNF4a to
bind to recognition sites was studied with 32P-labeled probes
encompassing predicted HNF4a-sites located in the AGTR1,
ACE, and ACE2 [ACE2(a) and ACE2(b)] gene. Predicted binding
sites were confirmed by EMSA bandshift assays using an antibody
specific for HNF4a. We observed strong binding of nuclear
extracts of untreated cell cultures to all predicted sites (Fig. 2A).
Addition of a specific HNF4a antibody shifted the bands, therefore
providing clear evidence for the specificity and selectivity of the
assay. Strikingly, cyclosporine significantly reduced binding of
HNF4a to all EMSA probes employed to approximately 60%
when compared to untreated cell cultures (Fig. 2B).
Cyclosporine inhibits protein expression of HNF4a
HNF4a protein expression was significantly repressed after
treatment of HepG2 cells with 10 mg/ml cyclosporine for 72 h
(Fig. 3A). For comparison Western blotting of actin was used as
housekeeping protein and to control loading onto the gel (Fig. 3A,
B). Protein expression of AGT and AGTR1 remained unchanged
after treatment with cyclosporine (Fig. 3C).
Discussion
Cyclosporine had been introduced for more then 20 years and
represents a major breakthrough in transplantation medicine.
Unfortunately, treatment of patients with calcineurin inhibitors
results in unwanted side effects, notably hypertension and
nephrotoxicity [1–3,5]. Although these adverse effects are already
Table 2. Real-Time PCR primer sequences and amplification settings.
Gene Accession number Primer sequence
Fragment
length Annealing Elongation Fluorescence
HNF4a NM_000457 fwd: CTGCTCGGAGCCACAAAGAGATCCATG
rev: ATCATCTGCCACGTGATGCTCTGCA
371bp 60uC 15sec 88uC
AGT NM_000029 fwd: GGATGAGAGAGAGCCCACAG
rev: CTCACTCCATGCAGCACACT
351bp 68uC 15sec 90uC
ACE NM_152830 fwd: ATGTAGATGCAGGGGACTCG
rev: CCAGGGAGGTGAAGAAATCA
342bp 60uC 14sec 88uC
ACE2 NM_021804 fwd: GATCCCATGGCTACAGAGGA
rev: GCCAGGAAGAGCTTGACATC
228bp 60uC 20sec 82uC
AGTR1 NM_000685 Exon2/Exon5
fwd: CTGATGCCATCCCAGAAAGT
rev: CTTCCAGCTTTGGGACAATC
144bp 60uC 20sec 78uC
Exon5/Exon5
fwd: CAAGACAAAGCAAAGCCACA
rev: CAGGACAAAAGCAGGCTAGG
136bp 60uC 20sec 78uC
mitATPase NC_012920 fwd: CTAAAGGACGAACCTGA
rev: TGGCCTGCAGTAATGTT
315bp 55uC 13sec 83uC
doi:10.1371/journal.pone.0016319.t002
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PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e16319Figure 1. Regulation of gene expression in HepG2 cells after cyclosporine treatment. A. Gene expression was measured by quantitative
real-time RT-PCR in HepG2 cells 72 h after treatment with 10 mg/ml cyclosporine (n=3, respectively) and was determined relative to expression of
mitATPase6, which served as a housekeeping gene. Gene expression in untreated HepG2 cells was set to 100 and values for cyclosporine treatment
represent transcript abundance relative to control. Non-parametric Mann-Whitney-U-Test was used to compare cyclosporine treated and control
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the molecular basis for cyclosporine induced hypertension remains
elusive.
Specifically, cyclosporine binds to the cyclophillin receptor. This
drug-receptor complex inhibits activation of the calcineurin
phosphatase, a secondary messenger in the dephosphorylation
and activation of nuclear factor of activation of T-cells (NFAT).
NFAT is a DNA-binding protein that promotes transcription of
interleukin-2 (IL-2) but inhibition of IL-2 production stops
proliferation and activation of T-cells to mediate the immunosup-
pressive effect of cyclosporine [46]. Indeed, activation of the RAS
system is one of the important mechanism involved in cyclosporine
induced hypertension and represents a coordinated hormonal
cascade of major importance in the control of cardiovascular and
renal tonus [18]. Cyclosporine causes RAS activation by an
increase in plasma renin and ACE activity with subsequent
generation of elevated AngII levels [18,20–24,34]. Furthermore,
long-term treatment with cyclosporine is associate with up-
regulated AGTR1 receptors in vascular and renal tissues [25–
28]. The exact molecular causes leading to RAS activation and
AngII increase are unknown; its activation is probably a
multifactorial process [18]. In addition to calcineurin inhibition,
cyclosporine stimulates PDGF [47] and TGFb [48,49] signaling
that seems to be involved in mediating renin secretory effects of
cyclosporine and it is well established that binding of AngII to
AGTR1 leads to vasoconstriction and hypertension. Thus, an
increase in blood pressure may contribute to renal damage and a
subsequent increase in plasma renin activity [18]. This process
may cause a vicious circle in RAS activation, which further
perpetuates cyclosporine toxicity. However, cyclosporine also
induces structural nephrotoxicity, which is independent of blood
pressure changes [18,25,34]. Taken collectively, cyclosporine
stimulates both, the systemic (circulating) RAS and the local
(tissue) RAS components, which were identified in many organs
[20]. In regards to the tissue RAS, AngII exerts further direct
effects on cardiac myocytes contributing to hypertension and
cardiac failure [50]. In this complex interplay HNF4a is one of the
direct NFAT target genes [37,51]. Recently, we demonstrated
recently its gene and protein expression to be significantly
repressed in response to cyclosporine treatment [37]. AGT is
known to be regulated by HNF4a [38] and we identified AGTR1
and ACE as further HNF4a target genes among RAS members.
We applied position weight matrices to predict HNF4a consensus
sites and confirmed the predictions experimentally by EMSA
assays to determine its DNA binding activity. Thus, we
demonstrate cyclosporine treatment of human hepatoma cells to
significantly reduce DNA-binding of HNF4a to AGT and
AGTR1 at gene specific promoters to cause impaired gene
expression. As alternative splicing might be an important
mechanism in the regulation of AGTR1 expression [44] we
analyzed AGTR1 isoforms before and after cyclosporine treat-
ment. Here, expression of splice variants was unchanged in
HepG2 cells. Furthermore, we analyzed the consequences of
inhibition of ACE in cyclosporine treated HepG2 cells. Captopril
groups. Results are considered significant at p,0.05 (marked with an asterik). AGT (angiotensinogen), AGTR1 (angiotensin II receptor, type 1), 2/5
(Primer Exon 2/Exon 5), 5/5 (Primer Exon 5/Exon 5), ACE2 (Angiotensin I converting enzyme 2). B and C. Gene expression of AGT and AGTR1 (2/5) (B)
or AGTR1 (5/5) (C) in HepG2 cells. Gene expression was determined by quantitative real-time RT-PCR in untreated HepG2 cells (n=11) and in
cyclosporine treated HepG2 cells (n=12). Linear regression of correlation with 0.95 confidence interval are shown. AGTR1 (2/5): r
2=0.3910, p=0.0014;
AGTR1 (5/5): r
2=0.2688, p=0.0113. AGT (angiotensinogen), AGTR1 (angiotensin II receptor, type 1), 2/5 (Primer Exon 2/Exon 5), 5/5 (Primer Exon 5/
Exon 5). D. Gene expression of HNF4a was measured by quantitative real-time RT-PCR in total RNA extracts obtained from cultures of primary human
hepatocytes treated with 30 mg/ml cyclosporine for 72h in n=3 replicates measurements. Expression of mitATPase6 served as a housekeeping gene.
Gene expression in untreated human hepatocytes was set to 100 and values for cyclosporine treatment represent transcript abundance relative to
control. Non-parametric Mann-Whitney-U-Test was used to compare cyclosporine treated and control groups. Results are considered significant at
p,0.05 (marked with an asterik).
doi:10.1371/journal.pone.0016319.g001
Table 3. Gene expression in HepG2 cells after treatment with captopril.
Gene Treatment
Transcript abundance
(relative units, mean ± SD) % of control
HNF4a Control 1.84660.127 100
Cyclosporine 0.99360.024 53.8
Cyclosporine + Captopril, 72h 1.20460.138 65.2
Cyclosporine + Captopril, 4h 1.10660.053 59.9
AGT Control 0.18660.026 100
Cyclosporine 0.07160.005 38.2
Cyclosporine + Captopril, 72h 0.07860.007 41.9
Cyclosporine + Captopril, 4h 0.07360.005 39.2
AGTR1 Control 0.33560.185 100
Cyclosporine 0.07560.010 22.4
Cyclosporine + Captopril, 72h 0.08760.022 26.0
Cyclosporine + Captopril, 4h 0.09560.006 28.4
Gene expression was measured by quantitative real-time RT-PCR in HepG2 cells after treatment with 10 mg/ml cyclosporine (n=3, respectively) for 72 h. Furthermore,
cells were treated in parallel with 10 mg/ml ACE inhibitor captopril (cyclosporine + captopril, 72h), or with cyclosporine for 72h and subsequently with 10 mg/ml
captopril for 4 h (cyclosporine + captopril, 4h). Transcript abundance of HNF4a, AGT, and AGTR1 are determined relative to expression of mitATPase6, which served as a
housekeeping gene. Data are given as relative units (mean 6 SD). Furthermore, transcript abundance of HNF4a, AGT, and AGTR1 in untreated HepG2 cells was set to
100 and values for cyclosporine or cyclosporine/captopril treatment represent transcript abundance relative to the control.
doi:10.1371/journal.pone.0016319.t003
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cyclosporine treated HepG2 cells. Hence, captopril selectively
inhibits ACE enzymatic activity, but did not affect gene expression
via feed back loops. However, RAS does not represent a linear
cascade, but is composed of a sophisticated interplay between
multiple mediators, receptors, and enzymes. The principal RAS
Figure 2. Cyclosporine inhibits binding of HNF4a to target genes. A. Electrophoretic mobility shift assays with 5 mg HepG2 cell nuclear
extract [control or cyclosporine treatment, 10 mg/ml for 72 h, n=3, respectively] and
32P labeled oligonucleotides to probe for DNA binding to HNF4a
binding-sites within HNF1a (HNF1), angiotensinogen (AGT), angiotensin II receptor, type 1 (AGTR1), angiotensin I converting enzyme (ACE1), and
angiotensin I converting enzyme 2 [ACE2(a), ACE2(b)] genes. In EMSA supershift assays an antibody directed against HNF4a (+) was added. Shifted
(HNF4a s) and supershifted bands (HNF4a ss) were marked. B. Dried EMSA gels were analyzed with a Molecular Imager (BioRad, Muenchen, Germany)
using the Quantity One software (BioRad, Muenchen, Germany). HNF4a binding of control extracts to the respective binding sites was set to 100%
and inhibition of binding to the respective binding sites after treatment with cyclosporine (10 mg/ml for 72 h) was quantified. Non-parametric Mann-
Whitney-U-Test was used to compare cyclosporine treated and control groups. Results are considered significant at p,0.05 (marked with an asterisk).
doi:10.1371/journal.pone.0016319.g002
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loops, e.g. induction of AGT [52] and a decrease in AGTR1 [44].
Furthermore, AngII acts at an additional membrane receptor,
AGTR2, which antagonizes AGTR1 induced signaling thereby
mediating vasodilatation, antiproliferative and apoptotic effects
[53]. Importantly, RAS can be envisioned as a dual function
system, in which the vasoconstrictor/vasodilator actions are
primarily driven by the ACE/ACE2 balance. Indeed, ACE2,
which was termed the alternative axis of RAS, efficiently
hydrolyses the octapeptide AngII to Ang(1-7), a peptide that
exerts actions opposite to those of AngII [54]. Ang(1-7) has
protective function; it binds to the G protein coupled receptor
Mas, acts as a vasodilator and antagonizes AngII-induced
vasoconstriction [54]. The impact of cyclosporine on ACE2
activity or expression was not analyzed so far. Bioinformatic
prediction of HNF4a binding sites and subsequent EMSA assays
identified ACE2 as a further HNF4a target gene, which was
significantly repressed after cyclosporine treatment of HepG2 cells.
As reported elsewhere a decrease in ACE2 leads unambiguously to
enhanced AngII action on AGTR1 and caused vasoconstriction
and hypertension [55]. Interestingly, ACE2 is markedly reduced in
rat models of hypertension [56]. It has been proposed that some of
the beneficial effects of currently used protective drugs as ACE
inhibitors and AGTR1 blockers are beyond their direct effects on
suppression of the ACE-AngII-AGTR1 axis as they also increased
Ang(1-7) production through feedback mechanisms [54]. Conse-
quently, ACE2 may represent a novel therapeutic target within the
RAS system by enhancing AngII degradation. Indeed, a potential
Table 4. Predicted binding sites for HNF4a in different genes of the renin-angiotensin system.
Gene name Oligo name Accession number bp relative to TSS
a Sequence Matrix Score core/matrix
AGTR1 AGTR1 NM_000685 +39426 to +39439 GAGGGCAAAGTTCA V$HNF4_Q6_01 1.000/1.000
ACE ACE1 NM_000789 24690 to 24668 CTACCAAAGGTCAG V$HNF4_Q6_01 1.000/0.909
ACE2 ACE2(a) NM_021804 24380 to 24358 ATGTACTTTGCTCT V$HNF4_Q6_01 1.000/0.969
ACE2 ACE2(b) NM_021804 26283 to 26261 GTGATCTTTGACTC V$HNF4_Q6_01 1.000/0.896
aTSS = transcription start site, NCBI GenBank Version Build 36.1 (hg18).
doi:10.1371/journal.pone.0016319.t004
Figure 3. Cyclosporine inhibits protein expression of HNF4a. A. HNF4a western blotting of 20 mg HepG2 cell nuclear extracts (upper panel)
and actin western blotting (lower panel) of 10 mg HepG2 cell nuclear extracts [control or cyclosporine treatment, 10 mg/ml for 72 h, n=3,
respectively]. B. The graph panel represent the quantification of protein amounts for HNF4a relative to the actin expression. Non-parametric Mann-
Whitney-U-Test was used to compare cyclosporine treated and control groups. Results are considered significant at p,0.05 (marked with an asterisk).
C. AGT, AGTR1, and actin western blotting of 30 mg, 20 mg and 15 mg total cellular extract, respectively, isolated from control or cyclosporine treated
HepG2 cells (10 mg/ml for 72 h, n=3, respectively).
doi:10.1371/journal.pone.0016319.g003
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treatment of hypertension was recently suggested [55].
In conclusion, we propose cyclosporine to cause dysfunction of
HNF4a which in turn disturbs the balance of the renin-
angiotensin-system. Most recently, Bai et al reviewed the genetic
basis for adverse drug effects of calcineurin inhibitors and
proposed that the development of type 2 diabetes, hypertension,
and renal failure may be associated with specific DNA genotypes
[57]. They conclude that disease-associated genes may provide
genomic biomarkers for exploring adverse drug effects. As there
are large individual differences in HNF4a expression amongst
patients as recently reported by us [37], patients with low HNF4a
activity might be at higher risk for developing cyclosporine
induced hypertension.
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